|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Quest Diagnostics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Quest Diagnostics, Inc. – Enzo Biochem, Inc. (ENZ-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1931 million, Net Earnings of USD 160 ... Read more (Read more...)
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.
Quest Diagnostics Inc. said on Thursday that despite greater-than-expected proposed cuts to Medicare reimbursement for lab tests, the company should still meet the guidance it has set for coming years. ...
Considering hurricanes related financial impact and recently-closed acquisitions, Quest Diagnostics' (DGX) management has revised its guidance for full year 2017.
On a per-share basis, the Madison, New Jersey-based company said it had net income of $1.15. Earnings, adjusted for one-time gains and costs, came to $1.39 per share. The results surpassed Wall Street ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. DGX credit default swap spreads are within the middle of their range for the last three years.
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $8.49 billion.
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Genomic Health, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Quest Diagnostics was the S&P 500's top loser on September 25. On September 25, Quest Diagnostics fell 7.4% to $94.38—the lowest close in seven months.
Announcement: Moody's: Proposed Medicare Lab Rate Cuts Would Be Credit Negative for Quest. Global Credit Research- 26 Sep 2017. New York, September 26, 2017-- Moody's Investors Service commented on the ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Genomic Health, Inc. Here are 5 ETFs with the largest exposure to GHDX-US. Comparing the performance and risk of Genomic Health, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
The Center for Medicare and Medicaid Services has released 2018 draft reimbursement rates for clinical lab tests and there are “few winners,” according to Canaccord Genuity analyst Mark Massaro.
Quest Diagnostics (DGX) isn’t the only medical testing laboratory chain that could get hit by a proposed cut to next year’s Medicare reimbursement rates. Closing at $94.60a share, Quest lost more than 7.3% in Monday market action, making it the worst-performing name in the benchmark index. Late Friday, the Center for Medicare and Medicare Services released draft Medicare reimbursement rates for 2018 that were far more severe than anyone expected.
Quest plunged to a seven-month low after health regulators proposed to cut lab test reimbursement rates by 9%-10% in 2018.
Nothing hits a healthcare services stock quite like Medicare cut. The market for medical testing services is dominated by two players, Quest Diagnostics (DGX) and LabCorp (LH). Late Friday, the Center for Medicare and Medicare Services released draft Medicare reimbursement rates for 2018 that were far worse than anyone expected.